Vascular risk factors and cognition in Parkinson's disease

Journal of Alzheimer's Disease

Volumn 51, Issue 2, 2016, Pages 563-570

  Pilotto, Andrea ^a,b   Turrone, Rosanna ^a   Liepelt Scarfone, Inga ^b,c   Bianchi, Marta ^a   Poli, Loris ^a   Borroni, Barbara ^a   Alberici, Antonella ^a   Premi, Enrico ^a,d   Formenti, Anna ^a   Bigni, Barbara ^a   Cosseddu, Maura ^a   Cottini, Elisabetta ^a   Berg, Daniela ^b,c   Padovani, Alessandro ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d Brescia Civic Hospital   (Italy)

Author keywords

Dementia; heart disease; hypertension; Parkinson disease; risk factors

Indexed keywords

AGED; ARTICLE; ATTENTION; COGNITION; DEMENTIA; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE DURATION; EXECUTIVE FUNCTION; FEMALE; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MANAGER; MILD COGNITIVE IMPAIRMENT; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; VASCULAR RISK FACTOR; DISABILITY; EDUCATIONAL STATUS; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOLOGY; SEX DIFFERENCE; TIME FACTOR; VASCULAR DISEASES;

AGE OF ONSET; AGED; ATTENTION; DISABILITY EVALUATION; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; HUMANS; MALE; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREVALENCE; RISK FACTORS; SEX FACTORS; TIME FACTORS; VASCULAR DISEASES;

EID: 84961833461     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150610     Document Type: Article

References (46)

1. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. (2006). Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study. Lancet Neurol 5, 735-741.
2. Haugarvoll K, Aarsland D, Wentzel-Larsen T, Larsen JP. (2005). The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 112, 386-390.
3. González-Redondo R, Toledo J, Clavero P, Lamet I, García- García D, García-Eulate R, Martínez-Lage P, Rodríguez- Oroz MC. (2012). The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease. Eur J Neurol 19, 1100-1107.
4. Sawek J, Roszmann A, Robowski P, Dubaniewicz M, Sitek EJ, Honczarenko K, Gorzkowska A, Budrewicz S, Mak M, Goab-Janowska M, Koziorowska-Gawron E, Dro'zdzik M, Kurzawski M, Bandurski T, Bia'ecka M. (2013). The impact of MRI white matter hyperintensities on dementia in Parkinson's disease in relation to the homocysteine level and other vascular risk factors. Neurodegener Dis 12, 1-12.
5. Emre M, Ford PJ, Bilgic B, Uc' EY(2014). Cognitive impairment and dementia in Parkinson's disease: Practical issues and management. Mov Disord 29, 663-672.
6. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22, 1689-1707; quiz 1837.
7. Litvan I, Goldman JG, Tr'oster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez- Oroz MC, Burn DJ, Barker RA, EmreM(2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 27, 349-356.
8. Irwin DJ, Lee VM-Y, Trojanowski JQ. (2013). Parkinson's disease dementia: Convergence of -synuclein, tau and amyloid- pathologies. Nat Rev Neurosci 14, 626-636.
9. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM-Y, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ. (2012). Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 72, 587-598.
10. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, De Silva R, Lees AJ, Revesz T. (2011). Lewy- and Alzheimertype pathologies in Parkinson's disease dementia: Which is more important'. Brain 134, 1493-1505.
11. Halliday GM, Leverenz JB, Schneider JS, Adler CH. (2014). The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord 29, 634-650.
12. Svenningsson P, Westman E, Ballard C, Aarsland D. (2012). Cognitive impairment in patients with Parkinson's disease: Diagnosis, biomarkers, and treatment. Lancet Neurol 11, 697-707.
13. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, Monsell SE, Kukull WA, Trojanowski JQ. (2013). Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 136, 2697-2706.
14. Jellinger KA. (2003). Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol 105, 415-419.
15. Jellinger KA. (2012). Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts. Mov Disord 27, 8-30.
16. Jellinger KA, Attems J. (2008). Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 115, 427-436.
17. Bohnen NI, Kotagal V, Müller MLTM, Koeppe RA, Scott PJH, Albin RL, Frey KA, Petrou M. (2014). Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 20, 1394-1398.
18. Giuntini M, Baldacci F, Del Prete E, Bonuccelli U, Ceravolo R. (2014). Diabetes is associated with postural and cognitive domains in Parkinson's disease. Results from a single-center study. Parkinsonism Relat Disord 20, 671-672.
19. Levy G, Tang M-X, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K. (2002). Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease'. An exploratory study. Mov Disord 17, 250-257.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181-184.
21. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, LeeVMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M. (2005). Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872.
22. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I. (1990). Variable expression of Parkinson's disease: A baseline analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40, 1529-1534.
23. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M. (2007). Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. Mov Disord 22, 2314-2324.
24. Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, Pezzella D, di Grazia A, Erro R, Pellecchia MT, Amboni M, Trojano L, Barone P. (2015). Mild cognitive impairment in newly diagnosed Parkinson's disease: A longitudinal prospective study. Parkinsonism Relat Disord 21, 1219-1226.
25. Heinzel S, Liepelt-Scarfone I, Roeben B, Nasi-Kordhishti I, Suenkel U, Wurster I, Brockmann K, Fritsche A, Niebler R, Metzger FG, Eschweiler GW, Fallgatter AJ, Maetzler W, Berg D. (2014). A neurodegenerative vascular burden index and the impact on cognition. Front Aging Neurosci 6, 161.
26. Hu MTM, Szewczyk-Królikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, Talbot K, Ebmeier KP, Mackay CE, Ben-Shlomo Y. (2014). Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord 29, 351-359.
27. Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, Morley JF, Chahine LM, Dahodwala N, Akhtar RS, Siderowf A, Trojanowski JQ, Weintraub D. (2015). Longitudinal study of normal cognition in Parkinson disease. Neurology 85, 1276-1282.
28. Cholerton BA, Zabetian CP, Wan JY, Montine TJ, Quinn JF, Mata IF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu S-C, Leverenz JB, Edwards KL. (2014). Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Mov Disord 29, 756-764.
29. Barton BR, Bernard B, Czernecki V, Goldman JG, Stebbins G, Dubois B, Goetz CG. (2014). Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. Mov Disord 29, 1252-1257.
30. Anang JBM, Gagnon J-F, Bertrand J-A, Romenets SR, Latreille V, Panisset M, Montplaisir J, Postuma RB. (2014). Predictors of dementia in Parkinson disease: A prospective cohort study. Neurology 83, 1253-1260.
31. Kim J-S, Oh Y-S, Lee K-S, Kim Y-I, Yang D-W, Goldstein DS. (2012). Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 79, 1323-1331.
32. Fereshtehnejad S-M, Romenets SR, Anang JBM, Latreille V, Gagnon J-F, Postuma RB. (2015). New clinical subtypes of Parkinson disease and their longitudinal progression: A prospective cohort comparison with other phenotypes. JAMA Neurol 72, 863-873.
33. Bell RD, Zlokovic BV. (2009). Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
34. Pimentel-Coelho PM, Michaud J-P, Rivest S. (2013). Effects of mild chronic cerebral hypoperfusion and early amyloid pathology on spatial learning and the cellular innate immune response in mice. Neurobiol Aging 34, 679-693.
35. Rektor I, Goldemund D, Sheardová K, Rektorová I, Michálková Z, Dufek M. (2009). Vascular pathology in patients with idiopathic Parkinson's disease. Parkinsonism Relat Disord 15, 24-29.
36. Rektor I, Goldemund D, Bedna'rík P, Sheardová K, Michálková Z, Telecká S, Dufek M, Rektorová I. (2012). Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease. Mov Disord 27, 1169-1172.
37. Miners JS, Palmer JC, Love S. (2015). Pathophysiology of hypoperfusion of the precuneus in early Alzheimer's disease. Brain Pathol. E-published. doi: 10.1111/bpa. 12331
38. Nishtala A, Himali JJ, Beiser A, Murabito JM, Seshadri S, Wolf PA, Au R. (2015). Midlife hypertension risk and cognition in the non-demented oldest old: Framingham heart study. J Alzheimers Dis 47, 197-204.
39. Zhao Q, Roberts RO, Ding D, Cha R, Guo Q, Meng H, Luo J, Machulda MM, Shane Pankratz V, Wang B, Christianson TJH, Aakre JA, Knopman DS, Boeve BF, Hong Z, Petersen RC. (2015). Diabetes is associated with worse executive function in both Eastern and Western Populations: Shanghai Aging Study and Mayo Clinic Study of Aging. J Alzheimers Dis 47, 167-176.
40. Nombela C, Rowe JB, Winder-Rhodes SE, Hampshire A, Owen AM, Breen DP, Duncan GW, Khoo TK, Yarnall AJ, Firbank MJ, Chinnery PF, Robbins TW, O'Brien JT, Brooks DJ, Burn DJ, BarkerRA(2014). Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain 137, 2743-2758.
41. Vale TC, Caramelli P, Cardoso F. (2015). Clinicoradiological comparison between vascular parkinsonism and Parkinson's disease. J Neurol Neurosurg Psychiatry 86, 547-553.
42. Bohnen NI, Müller MLTM, Zarzhevsky N, Koeppe RA, Bogan CW, Kilbourn MR, Frey KA, Albin RL. (2011). Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain 134, 2358-2365.
43. Vesel'y B, Rektor I. (2016). The contribution of white matter lesions. (WML). to Parkinson's disease cognitive impairment symptoms: A critical review of the literature. Parkinsonism Relat Disord 22(Suppl 1), S166-S170.
44. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, KannelWB(2008). General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 117, 743-753.
45. Yasar S, Xia J, YaoW, Furberg CD, Xue Q-L, Mercado CI, Fitzpatrick AL, Fried LP, Kawas CH, Sink KM, Williamson JD, DeKosky ST, Carlson MC. (2013). Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 81, 896-903.
46. Solfrizzi V, Scafato E, Frisardi V, Seripa D, Logroscino G, Kehoe PG, Imbimbo BP, Baldereschi M, Crepaldi G, Di Carlo A, Galluzzo L, Gandin C, Inzitari D, Maggi S, Pilotto A, Panza F. (2011). Angiotensin-converting enzyme inhibitors and incidence of mild cognitive impairment. The Italian Longitudinal Study on Aging. Age. (Omaha). 35, 441-453